Flunitrazepam: acute benefit-risk assessment in general practice.
A methodology is described which is practical in assessing the benefit-risk ratio of a single new drug prior to marketing. Flunitrazepam at doses of 0.5 mg, 1.0 mg (and 2 mg) nocte in 2,435 patients is shown to be effective in 78% of patients and the acute risk, predictable and low, irrespective of age or dose. One may conclude that the acute benefit-risk ratio is acceptable with respect to the class of drug and indication for which flunitrazepam is prescribed.
D000328:Adult; D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic; D005194:Family Practice; D005260:Female; D005445:Flunitrazepam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk
D005445:Flunitrazepam